Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
QiAn Biotech is a clinical-stage biopharmaceutical company based in Huzhou, China, dedicated to the development of innovative vaccines and therapeutics. The company utilizes a proprietary mRNA technology platform and recombinant protein expertise to target high-burden infectious diseases and oncology. Its lead candidate, QA-B01, is an mRNA-based COVID-19 vaccine that has advanced into clinical trials. QiAn Biotech integrates advanced antigen design with optimized lipid nanoparticle (LNP) delivery systems to create effective and accessible immunization solutions. The company's broader pipeline includes programs for shingles, HPV, and respiratory syncytial virus, aiming to address significant unmet global health needs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Qi An.